Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 19, 2025
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 19, 2025
Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and remains on track to file for U.S. device …
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
GlobeNewswire
·
May 19, 2025
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC …
KabaFusion Acquires Infusion Care Assets from Coram® to Expand its Nationwide Footprint of Patient-Focused Services
GlobeNewswire
·
May 19, 2025
LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- KabaFusion, a nationally recognized leader in home and alternative site infusion, today announced it has closed on a transaction with Coram pursuant to which it has acquired 6 locations that will serve as …
Aurora Spine Corporation Schedules Release of First Quarter Fiscal 2025 Financial Results
GlobeNewswire
·
May 19, 2025
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced it will …
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 19, 2025
WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement …
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
GlobeNewswire
·
May 19, 2025
-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small interfering RNA (siRNA) for the treatment of thromboembolic disorders- -SRSD107 demonstrated peak …
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
GlobeNewswire
·
May 19, 2025
Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammation Novel bispecific design shows promising potential …
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
GlobeNewswire
·
May 19, 2025
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and …
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
GlobeNewswire
·
May 19, 2025
DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., …
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
GlobeNewswire
·
May 19, 2025
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, …
Lysosomal Storage Disorders Market Set to Expand Across the 7MM During the Forecast Period (2025–2034) with Advances in Enzyme Replacement Therapies | DelveInsight
GlobeNewswire
·
May 19, 2025
New York, USA, May 19, 2025 (GLOBE NEWSWIRE) -- Lysosomal Storage Disorders Market Set to Expand Across the 7MM During the Forecast Period (2025–2034) with Advances in Enzyme Replacement Therapies | DelveInsight The lysosomal storage disorders market is …
Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo
GlobeNewswire
·
May 19, 2025
Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B), in patients with …
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
GlobeNewswire
·
May 19, 2025
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT-621 Phase 1 healthy volunteer SAD/MAD trial completed with …
The Coalition to Transform Clinical Trial Engagement Launches National “Champions for Change – PTO Initiative” to Expand Access to Clinical Trials for Working Patients with 7 Corporate and Non-Profit Members
GlobeNewswire
·
May 19, 2025
CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- In recognition of Clinical Trials Day, the Coalition to Transform Clinical Trial Engagement (CTCTE) proudly announces the launch of the Champions for Change – Paid Time Off (PTO) Initiative, a national effort to …
PhotoniCare's OtoSight Demonstrates More Accurate Diagnosis and a 50 Percent Reduction in Antibiotic Usage for Pediatric Ear Infections in Large Randomized Controlled Trial
GlobeNewswire
·
May 19, 2025
DURHAM, N.C. and GRAND RAPIDS, Mich., May 19, 2025 (GLOBE NEWSWIRE) -- PhotoniCare Inc., a medical device company dedicated to delivering innovation to frontline care that demonstrably enhances patient outcomes, is pleased to announce its progress in the …
Healthcare Consulting & Contracting (HC3) Founder and Senior Toxicologist Dr. J. David Krause Honored with AIHA’s 2024 Lila Albin Best IEQ Paper Award
GlobeNewswire
·
May 19, 2025
Tallahassee, Florida , May 19, 2025 (GLOBE NEWSWIRE) -- Healthcare Consulting …
Dr. Yesmean Wahdan from Bayer Discusses Women’s Health Month with YourUpdateTV
GlobeNewswire
·
May 19, 2025
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- May marks Women’s Health Month, a timely reminder that while many women prioritize the health of others, their own well-being matters just as much. Recently, Dr. Yesmean Wahdan, Board-Certified OB/GYN and Medical …
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
GlobeNewswire
·
May 19, 2025
NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that …
American Kidney Fund’s Kidney Health for All™ Health Equity Media Campaign Expands to More Communities Nationwide
GlobeNewswire
·
May 19, 2025
ROCKVILLE, Md., May 19, 2025 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) has launched the next phase of its national Kidney Health for All™ media campaign, connecting millions more people with resources to help prevent kidney disease in high-risk …
Nika Pharmaceuticals, Inc. (NIKA) Markets Analysis and €8.5 Billion Projected Revenue
GlobeNewswire
·
May 19, 2025
HENDERSON, Nev., May 19, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) presents projected revenue for each market with exclusive distribution agreement. NIKA has previously reported an estimated potential €7.9 billion in revenue from …